News

Delirium is a frequent occurrence among children hospitalized with cancer, affecting nearly one in five patients, according to new research from Weill Cornell Medicine and NewYork-Presbyterian.

The study, published Nov. 21 in the Journal of Pediatrics, revealed that children who were either younger than 5 years old, had an underlying brain tumor, were recovering from surgery or receiving benzodiazepines — a class of drugs that treat anxiety, nervousness, seizures and other conditions by altering chemical signals in the brain — were at greatest risk for delirium, a mental state characterized by changes in alertness, cognition or awareness. The investigators say their findings demonstrate that children with cancer are at risk for developing delirium, and underscore the importance of routine screenings for the condition, which is associated with poor health outcomes, prolonged hospital stays and increased distress for patients and their families.

Analise Scarpaci's career debut also changed her long-term health.
Dr. Barry Kosofsky spoke on concussion impacts for teens.

Presented by M. Virginia Pascual, MD Director, Gale and Ira Drukier Institute for Children’s Health Ronay Menschel Professor of Pediatrics Weill Cornell Medicine

Rett Syndrome: From the Clinic to Genomes, Epigenomes, and Neural Circuits featuring Huda Y. Zoghbi, MD Ralph D. Feigin Professor of Pediatrics, Neuroscience, and Molecular and Human Genetics at Baylor College of Medicine Investigator, Howard Hughes Medical Institute Director, Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital Reception to follow at 5:00 PM. Rett syndrome is a delayed-onset childhood disorder, typically found in girls, that causes a broad range of severe neuropsychiatric disabilities, including loss of the ability to speak and socialize, and the development of tremors, ataxia, seizures, and stereotypic hand-wringing movements. The Zoghbi lab discovered that mutations in the gene MECP2 cause Rett syndrome, and before long it became clear that mutations in MECP2 can also cause autism and other neuropsychiatric phenotypes. Using genetically-engineered mice, the Zoghbi lab learned that the brain is acutely sensitive to MeCP2 levels; both decreases and increases in the amount of MeCP2 protein can lead to neurological problems that are also observed in humans. The research team showed that normalizing MeCP2 levels can reverse disease-like features in a mouse model of the human MECP2 duplication syndrome, a disorder that is usually found in boys and results from excess MeCP2. Zoghbi and collaborators have been gradually pinpointing the neurons and circuit abnormalities that mediate various symptoms.

Pediatrics Weill Cornell Medicine Appointments & Referrals: (646) 962-KIDS (646) 962-5437 Chair's Office: Weill Cornell Medicine 525 E 68th St.
Box 225
New York, NY 10065 (646) 962-5437